Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| But we're very confident in our ability to continue to grow the franchise |
| To summarize, 2023 was another strong year |
| Our growth in the year benefited from several tailwinds, including improvements in supply in certain markets, as well as competitive out of stocks |
| Our companion animal portfolio remains a key growth driver, up 8% operationally, and we saw a return to growth for our livestock portfolio, up 6% operationally |
| The animal health industry is resilient even in times of uncertainty, and we are poised to navigate these challenges because our portfolio diversity, our commitment to exceptional customer experience, operational excellence and agility, and we look forward to keeping you updated on our progress on future calls |
| Our track record of innovation, from pioneering breakthroughs to product lifecycle enhancements, has solidified our position as the industry leader, consistently growing above the market and enables us to create market-leading franchises |
| The launch of Librela and Solensia, the first two injectable monoclonal antibodies for the alleviation of osteoarthritis, is fundamentally improving the quality of life for dogs and cats, and strengthening the human-animal bond |
| Morgan Healthcare Conference, I shared that our own pain franchise could have peak sales exceeding $1 billion, and we are excited about Librela's performance since its US launch in October, which reaffirms that view |
| Our current clinic penetration levels for Librela in the US are exceeding our expectations, and as Kristin mentioned, we have launched our DTC efforts ahead of schedule to drive increased pet owner awareness |
| Similarly, Solensia has also been well received, with strong clinic penetration around the world, with increased opportunity as we generate more awareness of OA pain in cats |
| Within our dermatology franchise, we've established ourselves as the trusted partner to veterinarians, and after nearly a decade of impressive growth, we still believe we have room to expand this market |
| In our key dermatology products, we are prepared for competition and confident in our ability to defend and grow our share through our three differentiated dermatology products, the strength of our customer relationships, and the expertise we have gained from almost 10 years in the space |
| We remain confident that we can sustain growth thanks to our differentiated products like Cytopoint and Apoquel chewable, the first and only chewable treatment for the control of allergic itch and inflammation in dogs |
| And with their support, I want to reiterate that we expect to grow faster than the market again in 2024, not just in line, and to grow operational revenue by mid to high single digits |
| This continued success highlights our strategic execution, label strength, and the efficacy of our products |
| The performance across our key product franchises not only reinforces our market-leading position, but also better innovation consistently meet the evolving demands in veterinary medicine |
| For livestock, 2023 exceeded our expectations |
| Two durable global trends give us confidence in that future growth, the powerful human-animal bond, and the world's growing need for a sustainable supply of animal protein |
| Our commitment to operational excellence ensures we are ready to scale to meet those demands and navigate unforeseen challenges, while delivering shareholder value |
| Our companion animal portfolio was the main driver of revenue growth in the quarter, growing 10% operationally |
| Our dedication to innovation remains the cornerstone of our market-leading position |
| We continue to grow share even in spaces where we face new competition, and we remain confident in our ability to expand existing markets and create new ones in the future |
| So, we're very pleased with what we're seeing |
| As you've heard me say time and time again, we are confident in our strategy, portfolio, pipeline, and capabilities to deliver value to shareholders and customers, while performing above the market |
| Our focus positions us well to navigate potential challenges and capitalize on emerging opportunities |
| Trio grew 17% in the US in Q4, and we continue to gain patient share, which means again, switching is low when you have a product that's safe, efficacious, and been in the market for almost four years now |
| Adjusted net income grew 6% operationally, and adjusted diluted EPS grew 7% operationally for the quarter |
| We will grow revenue faster than the market |
| Trio, as we've said, we've seen really strong performance in Trio, posting double-digit growth |
| So, we really are seeing really strong growth, obviously overall in revenue, and we're much more correlated over time with that, just given the strength of our portfolio, et cetera |
| Statement |
|---|
| Additionally, while China represents less than 5% of our global revenues, the ongoing economic weakness there continues to impact our business, and represented a half a percentage point drag on our total company operational revenue growth for the year, entirely in volume |
| China represented a 3% drag on our international segment operational revenue growth in the quarter |
| China had an unfavorable impact on our international livestock sales in the quarter, particularly in our swine portfolio |
| Our full-year revenue was near the top end of our guidance range, while our adjusted net income was slightly below our guidance range, primarily due to the impact of foreign exchange, as well as an impairment charge related to a prior acquisition |
| You continue to see consumer confidence being low and swine prices remaining fairly depressed in consumption there as well |
| On an operational basis, adjusted gross margins decreased by 20 basis points, resulting primarily from higher manufacturing costs, which were partially offset by price increases and lower freight costs |
| And then you have China, which clearly started to more deteriorate in terms of the economic conditions there throughout the year |
| Lastly, while we are not assuming a change in the current economic situation in China, we do expect a headwind to growth, especially in the first half as the situation worsened over the course of 2023 |
| This growth was partially offset by a 33% operational decline in our Revolution franchise, which generates a high proportion of sales in China where we had a tough comparative quarter due to the return of supply in Q4 of 2022, as well as the ongoing impact of the current economic conditions |
| At adjusted net income, we expect FX to negatively impact our growth by 150 basis points, with significant unfavorable impact in the first half of the year, transitioning to slight favorability in the second half of the year |
| At net revenue, we expect foreign exchange to negatively impact our growth by 90 basis points, with the impact being more pronounced early in the year and decreasing later in the year |
| We are expecting foreign exchange to have an unfavorable impact on our growth versus the prior year |
| So, I want to - just given what you did in 4Q, a major focus point, is something like $200 million to $250 million for Librela for 2024 reasonable? And especially - that's for US, but then on the O-US side, we've heard some concerns maybe coming out of Europe |
| In fact, we'll see some declining comps in the first half on China |
| These investments are driving short-term margin impacts from lower site utilization |
| There remains some capacity issues in the US, but I think some of that's being addressed by more stuff going to auto-ship and retail and online, which has also been supporting it |
| I mean, obviously, they're not inconsequential |
| Now, moving on to the rest of the P&L, for the quarter adjusted gross margins of 67.1% decreased 100 basis points on a reported basis compared to the prior year |
| And you called out some headwinds during the call in terms of FX |
| Clearly, there's an impact on top line that we've talked about, but there's also a little bit of a delayed effect if you look at the impact it has on inventory and receivables that are on the books at the time |
Please consider a small donation if you think this website provides you with relevant information